{"meta":{"query_hash":"b440a9f20b63","filters":{"venue":"Generics and Biosimilars Initiative Journal"},"cohort_total":14,"direct_labels_cover":1,"predictions_cover":14,"exported":14,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/b440a9f20b63","api":"https://metacan.xera.ac/api/v1/cohort?venue=Generics+and+Biosimilars+Initiative+Journal"},"results":[{"id":"W2320750953","doi":"10.5639/gabij.2014.0303.033","title":"Subsequent entry biologics (biosimilars) in Canada: approaches to interchangeability and the extrapolation of indications and uses","year":2014,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Biosimilar; Interchangeability; Extrapolation; Business; Medicine; Computer science; Mathematics; Internal medicine","score_opus":0.14093827632215705,"score_gpt":0.2574729309045367,"score_spread":0.11653465458237966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320750953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8827823,0.011968497,0.00794601,0.09509326,0.00049788016,0.0007064041,0.0002455387,0.00001093047,0.0007492256],"genre_scores_gemma":[0.983778,0.002496481,0.0023221725,0.011345522,0.000031245247,0.000010291373,0.000006721511,0.000006218883,0.000003378123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822205,0.000777609,0.00044919297,0.00024536156,0.000059671438,0.00024608918],"domain_scores_gemma":[0.99890256,0.0005982154,0.000228049,0.00012803236,0.00007298473,0.00007018448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015239815,0.00017155948,0.00037055617,0.00012394373,0.00019470441,0.000028987542,0.00013389332,0.00015262565,0.000021016518],"category_scores_gemma":[0.0004557069,0.000102923674,0.000041098694,0.0002104317,0.00068033533,0.000055567987,0.00015297637,0.00036370818,1.5923091e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017265507,0.0004242773,0.7534044,0.0002362489,0.0010095423,0.000011371398,0.007081868,0.000030559815,0.038702358,0.009543218,0.02751872,0.1603109],"study_design_scores_gemma":[0.0050855046,0.0009357042,0.90608007,0.00021249415,0.00033473474,0.0003383326,0.004973345,0.0010640493,0.039301064,0.020833561,0.020099068,0.0007420559],"about_ca_topic_score_codex":0.00062583614,"about_ca_topic_score_gemma":0.025264857,"teacher_disagreement_score":0.15956883,"about_ca_system_score_codex":0.00007367395,"about_ca_system_score_gemma":0.00014925556,"threshold_uncertainty_score":0.9925215},"labels":[],"label_agreement":null},{"id":"W2326320320","doi":"10.5639/gabij.2015.0401.009","title":"Health Canada’s perspective on the clinical development of biosimilars and related scientific and regulatory challenges","year":2015,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Biosimilar; Perspective (graphical); Regulatory science; Business; Medicine; Computer science; Internal medicine; Pathology","score_opus":0.15669981788227194,"score_gpt":0.3526119372573578,"score_spread":0.19591211937508585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326320320","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3654431,0.14415894,0.00011147054,0.48310456,0.003090831,0.00059222366,0.00014465864,0.000027198663,0.0033269955],"genre_scores_gemma":[0.9533316,0.01263697,0.0037117447,0.030093515,0.00008731461,0.000005166627,0.000007694051,0.000028152946,0.000097845],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758947,0.0008438134,0.000675603,0.00039320727,0.00015510798,0.00034279685],"domain_scores_gemma":[0.99844027,0.00037759054,0.00043901915,0.00017302402,0.00037159433,0.000198495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038417608,0.00022515206,0.0004744995,0.000120576115,0.00068110414,0.000050211787,0.00015201845,0.00021469773,0.000022300543],"category_scores_gemma":[0.00044133601,0.00013705566,0.000055452292,0.00016329868,0.0013007665,0.000055620745,0.00016150769,0.00061418524,6.336227e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006465577,0.0006012478,0.0082795415,0.00009651573,0.0021410822,0.000054778575,0.014028037,0.0000021520225,0.0042167353,0.0073948707,0.85412127,0.10841724],"study_design_scores_gemma":[0.0077817226,0.0049634753,0.3357602,0.0008513947,0.00040972137,0.001835141,0.066248804,0.00010751078,0.030544685,0.023763979,0.52600414,0.0017291899],"about_ca_topic_score_codex":0.00003707498,"about_ca_topic_score_gemma":0.0040201317,"teacher_disagreement_score":0.5878885,"about_ca_system_score_codex":0.00014621008,"about_ca_system_score_gemma":0.0016270148,"threshold_uncertainty_score":0.5588967},"labels":[],"label_agreement":null},{"id":"W2488281113","doi":"10.5639/gabij.2016.0502.016","title":"Biosimilars patent litigation in Canada and Japan: a comparative strategic overview and EU and US update","year":2016,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Amgen Canada","keywords":"Biosimilar; Business; International trade; Law and economics; Economics; Medicine; Internal medicine","score_opus":0.12163815628710273,"score_gpt":0.28716337448201146,"score_spread":0.16552521819490873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488281113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94992435,0.026133234,0.00009540003,0.022867702,0.0002834744,0.00020895811,0.00027511799,0.000008373385,0.00020339314],"genre_scores_gemma":[0.92906857,0.04626919,0.00076443347,0.023818964,0.00003993197,0.0000066561297,0.000008141542,0.000012822439,0.000011310882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812454,0.0004484861,0.0004953631,0.00040916094,0.000085771935,0.00043669465],"domain_scores_gemma":[0.999118,0.00024673017,0.0002494528,0.000103280174,0.00012404252,0.00015854338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055127364,0.0003119419,0.0005262751,0.0001386053,0.00026063411,0.00008344513,0.00009030852,0.00019914987,0.000095127805],"category_scores_gemma":[0.000045031324,0.00019560075,0.000037781785,0.00018240574,0.0005189302,0.00016862074,0.00014250142,0.00036924725,8.645315e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012010386,0.00042739822,0.5381275,0.00038429757,0.0018464322,0.0003965144,0.0023698166,0.0000041398384,0.2941873,0.0029683118,0.0658994,0.092187874],"study_design_scores_gemma":[0.0094507495,0.0017079695,0.8718889,0.0011279562,0.00045105722,0.002450103,0.004599051,0.0004035135,0.04522825,0.01368828,0.047165673,0.0018385086],"about_ca_topic_score_codex":0.0008760661,"about_ca_topic_score_gemma":0.046359237,"teacher_disagreement_score":0.33376142,"about_ca_system_score_codex":0.00011335711,"about_ca_system_score_gemma":0.00027392188,"threshold_uncertainty_score":0.9710422},"labels":[],"label_agreement":null},{"id":"W2493092156","doi":"10.5639/gabij.2016.0502.014","title":"Adjusted indirect comparisons between generics – bioequivalence and interchangeability","year":2016,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Interchangeability; Bioequivalence; Medicine; Pharmacology; Computer science; Pharmacokinetics","score_opus":0.2569267108682741,"score_gpt":0.31465631857701165,"score_spread":0.05772960770873753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2493092156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8195518,0.010891667,0.023116875,0.13642408,0.0010600995,0.00035975498,0.0028842161,0.000057005618,0.005654467],"genre_scores_gemma":[0.953549,0.01665454,0.0020047468,0.027217153,0.00051371846,0.000008596402,0.0000062887684,0.000028880298,0.000017050785],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983223,0.00006773606,0.00071212923,0.00040869167,0.00004724344,0.0004418655],"domain_scores_gemma":[0.99869084,0.00021180371,0.0004685329,0.00017312834,0.00006756347,0.0003881319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092031946,0.00023967441,0.00054158655,0.00025576475,0.00025963757,0.00014596005,0.0002173213,0.00014392239,0.00017949136],"category_scores_gemma":[0.00018530313,0.0001921394,0.0000989534,0.00019934136,0.00035672824,0.00028931166,0.00022266535,0.00028099716,0.000029050652],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054565236,0.000119402874,0.8289026,0.0000551865,0.0003496852,0.00001639149,0.00078787375,0.000002245309,0.0010090874,0.0020994674,0.13765924,0.02894426],"study_design_scores_gemma":[0.0025908845,0.00057506433,0.46298024,0.00010534228,0.00008443431,0.0001452027,0.00020913205,0.0012383888,0.0034277886,0.055438884,0.47204575,0.001158912],"about_ca_topic_score_codex":0.0000010670011,"about_ca_topic_score_gemma":0.00000870591,"teacher_disagreement_score":0.36592236,"about_ca_system_score_codex":0.00012337735,"about_ca_system_score_gemma":0.000039466147,"threshold_uncertainty_score":0.7835217},"labels":[],"label_agreement":null},{"id":"W2547846819","doi":"10.5639/gabij.2016.0503.032","title":"Are the perspectives regarding the use of biosimilars in the setting of haematology and blood and marrow transplant changing?","year":2016,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Hematology; Medicine; Internal medicine; Intensive care medicine","score_opus":0.06043340861617394,"score_gpt":0.27414360920156383,"score_spread":0.2137102005853899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547846819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88615847,0.014735357,0.00064820173,0.09782127,0.00016022591,0.0002537235,0.00017234794,0.000005180607,0.000045214085],"genre_scores_gemma":[0.98102266,0.0103908,0.0006099934,0.007918469,0.000035668632,0.000005428416,6.7650853e-7,0.000009687638,0.00000659743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979889,0.000959235,0.0004218788,0.00022419628,0.00007823803,0.00032758966],"domain_scores_gemma":[0.9976731,0.0015105695,0.0004938637,0.00016656316,0.00012935748,0.000026579974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016301429,0.00019623288,0.00041450234,0.00015584056,0.0003865729,0.000040041345,0.00021226301,0.00018392627,0.000016307775],"category_scores_gemma":[0.000368821,0.00007382371,0.0000916412,0.00026957178,0.0012799547,0.000098273216,0.00010909626,0.0003917039,9.47918e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087767333,0.0005046506,0.49130753,0.00024232134,0.0023514698,0.0002785777,0.047998823,0.000003744227,0.41569272,0.002336043,0.022429563,0.015976902],"study_design_scores_gemma":[0.010465171,0.00235633,0.49325812,0.002816594,0.0028268718,0.023615858,0.15549763,0.00022550875,0.27430415,0.007530812,0.02556584,0.001537114],"about_ca_topic_score_codex":8.646553e-7,"about_ca_topic_score_gemma":0.00002502526,"teacher_disagreement_score":0.14138858,"about_ca_system_score_codex":0.000008511905,"about_ca_system_score_gemma":0.000025377069,"threshold_uncertainty_score":0.47160465},"labels":[],"label_agreement":null},{"id":"W3047360337","doi":"10.5639/gabij.2020.0901.005","title":"It is time to change US trade policy to foster access to medicines","year":2020,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Negotiation; Biosimilar; Balance (ability); Business; Access to medicines; Sustainability; International trade; International economics; Economics; Economic growth; Political science; Medicine; Developing country; Law","score_opus":0.24197099643837727,"score_gpt":0.3549841684586827,"score_spread":0.11301317202030542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047360337","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033036915,0.0004938664,0.0007714231,0.9836418,0.0002366159,0.00034943834,0.0008442479,0.0000132134755,0.010345684],"genre_scores_gemma":[0.013691104,0.0010393392,0.00065875443,0.9823121,0.0022217925,0.000026351689,0.000004581224,0.000034704797,0.000011304944],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983526,0.00002250931,0.00063287595,0.00042195187,0.000065289896,0.00050478097],"domain_scores_gemma":[0.9982475,0.00004151148,0.00020439952,0.00013845194,0.00004537789,0.0013227405],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032650525,0.0002530052,0.00050938345,0.00042924535,0.00018051277,0.00034064028,0.00043882686,0.00009326837,0.0011357549],"category_scores_gemma":[0.00019916578,0.00025134414,0.00011107652,0.000672654,0.000035989127,0.00031169917,0.00033676458,0.00024386492,0.00074828387],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000442651,0.00002432208,0.0017192968,0.000011777191,0.000058325084,0.000010710915,0.0038075869,0.000019090798,0.00016242448,0.000017114713,0.991272,0.002853089],"study_design_scores_gemma":[0.0004523714,0.00040331922,0.00601594,0.00002329949,0.0000112958205,0.000017901295,0.00004803901,0.00092870585,0.00058913295,0.0011917218,0.9899622,0.00035602495],"about_ca_topic_score_codex":4.2711486e-7,"about_ca_topic_score_gemma":0.000005164245,"teacher_disagreement_score":0.010387412,"about_ca_system_score_codex":0.00010641686,"about_ca_system_score_gemma":0.000053359563,"threshold_uncertainty_score":0.99999386},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3110075982","doi":"10.5639/gabij.2020.0903.022","title":"3rd Colombian educational workshop on regulatory assessment of biosimilars 2019 – Report","year":2020,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Pharmacovigilance; Workgroup; Medicine; Quality (philosophy); Health professionals; Political science; Medical education; Health care; Pharmacology; Adverse effect; Computer science; Law","score_opus":0.058383037059144174,"score_gpt":0.34017598766712337,"score_spread":0.2817929506079792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110075982","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15513977,0.012358349,0.0061872974,0.79902405,0.005639231,0.001110246,0.0009685517,0.00010510007,0.019467374],"genre_scores_gemma":[0.75357354,0.0053786584,0.024351845,0.21508415,0.0008348809,0.000019898902,0.00017001298,0.00008186448,0.0005051814],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997684,0.00041844617,0.0008258312,0.0004651626,0.00019779237,0.00040875407],"domain_scores_gemma":[0.9981544,0.00038632442,0.00067820615,0.00024620557,0.00034112396,0.00019370962],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009029177,0.000318471,0.00057518604,0.00016616716,0.00032879322,0.00005340594,0.00027972952,0.00038158617,0.0005442948],"category_scores_gemma":[0.00043077726,0.00025107243,0.00022682245,0.00039292828,0.0005374479,0.00010743383,0.00014573337,0.00082951324,0.000006126875],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020025075,0.00038049612,0.012526432,0.000035880996,0.00059961696,0.00008410366,0.00022610869,0.000018142646,0.072797164,0.00046544833,0.90848285,0.004183509],"study_design_scores_gemma":[0.0051496886,0.0040546497,0.38402346,0.0005363307,0.0008081343,0.0023553648,0.0017536136,0.00038492423,0.12647307,0.004381931,0.46825626,0.0018225497],"about_ca_topic_score_codex":1.8215887e-7,"about_ca_topic_score_gemma":0.0000016126346,"teacher_disagreement_score":0.59843373,"about_ca_system_score_codex":0.00007127817,"about_ca_system_score_gemma":0.00041042818,"threshold_uncertainty_score":0.99999416},"labels":[],"label_agreement":null},{"id":"W3119789362","doi":"10.5639/gabij.2021.1002.008","title":"Variation in the prices of oncology medicines across Europe and the implications for the future","year":2021,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadiana.org","funders":"","keywords":"Reimbursement; Population; Medicine; Per capita; Gross domestic product; Erlotinib; Life expectancy; Health care; Economics; Cancer; Internal medicine; Economic growth; Environmental health","score_opus":0.05162742510960357,"score_gpt":0.30450677715381375,"score_spread":0.2528793520442102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119789362","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.090962045,0.07774257,0.021813326,0.8025068,0.0011790042,0.0005539256,0.0005506737,0.000003844456,0.004687816],"genre_scores_gemma":[0.82029223,0.1059027,0.0010905726,0.07139515,0.0012307353,0.00005258856,0.00000654465,0.000013618996,0.000015848798],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9992751,0.000044291897,0.00040135096,0.00012049654,0.0000202454,0.0001385524],"domain_scores_gemma":[0.9987414,0.0004998333,0.0004811168,0.00011511992,0.00013852991,0.00002401737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015492917,0.00007557993,0.00022721737,0.00003156738,0.0003334435,0.000088331086,0.00016110818,0.000057148896,0.000009249998],"category_scores_gemma":[0.0002845168,0.000039727747,0.00004984978,0.00019368912,0.0002215304,0.000114447575,0.00004350842,0.00016735913,3.3220397e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054493686,0.00035419397,0.105817914,0.00010948893,0.0006805038,0.000011394781,0.068896,0.00024043855,0.000412463,0.5928348,0.124828026,0.105269864],"study_design_scores_gemma":[0.0014359526,0.00011200504,0.6044384,0.000008868872,0.000024297004,0.00007039752,0.0026186828,0.00040554433,0.000018052888,0.060537405,0.33024952,0.00008084278],"about_ca_topic_score_codex":0.0000020210466,"about_ca_topic_score_gemma":0.00009178259,"teacher_disagreement_score":0.73111165,"about_ca_system_score_codex":0.0000230791,"about_ca_system_score_gemma":0.00007100893,"threshold_uncertainty_score":0.25646114},"labels":[],"label_agreement":null},{"id":"W3216742648","doi":"10.5639/gabij.2021.1003.016","title":"A critical review of substitution policy for biosimilars in Canada","year":2021,"lang":"en","type":"review","venue":"Generics and Biosimilars Initiative Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Competition (biology); Business; Market competition; Public economics; Marketing; Medicine; Economics; Market economy","score_opus":0.21793994318783752,"score_gpt":0.38310764969058575,"score_spread":0.16516770650274823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216742648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000022755382,0.980559,0.0002693212,0.013752228,0.000577302,0.00040457683,0.0035455602,0.000002424411,0.00088733796],"genre_scores_gemma":[0.000015646325,0.9408448,0.0005960849,0.058003925,0.0003712407,0.00004911429,0.000079329715,0.000037490543,0.0000023756452],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967796,0.00010138561,0.0021057383,0.00043675076,0.00006635862,0.00051012996],"domain_scores_gemma":[0.9978085,0.00040155032,0.0011234649,0.00021414655,0.00017654117,0.00027576942],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010295104,0.0003920257,0.0026000151,0.0004893036,0.00011433661,0.000073108116,0.00029578383,0.00021295663,0.00013250425],"category_scores_gemma":[0.0014114714,0.0003906618,0.000507506,0.0006122927,0.00013086866,0.0001420823,0.00011339146,0.00055547676,0.0000024991025],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021404101,0.00031427306,0.00033927354,0.15958695,0.0010075764,0.00016684711,0.00008663859,0.000008048853,8.681021e-7,0.06856056,0.49760902,0.27229854],"study_design_scores_gemma":[0.00027212023,0.000044248347,0.000015406793,0.019636437,0.00012363885,0.00012724464,0.000009671651,0.00008699213,0.0000031364257,0.0037358631,0.9755476,0.00039763324],"about_ca_topic_score_codex":0.0005993452,"about_ca_topic_score_gemma":0.0058799423,"teacher_disagreement_score":0.4779386,"about_ca_system_score_codex":0.001058837,"about_ca_system_score_gemma":0.004143869,"threshold_uncertainty_score":0.9998545},"labels":[],"label_agreement":null},{"id":"W4229584754","doi":"10.5639/gabij.2014.0401.012","title":"Comparison of biosimilars guidelines","year":2014,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Business; Medicine; Internal medicine","score_opus":0.14024363653818273,"score_gpt":0.40170539137391414,"score_spread":0.2614617548357314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229584754","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2513455,0.10981876,0.18425664,0.40295744,0.015164405,0.0015383427,0.0008915845,0.0003578446,0.033669483],"genre_scores_gemma":[0.82636,0.0049005346,0.055849932,0.112111844,0.00053351093,0.000007608195,0.00002949478,0.000060796858,0.00014628553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779284,0.00045689143,0.0009378687,0.00029070734,0.000113481656,0.00040823309],"domain_scores_gemma":[0.9983089,0.00029166465,0.00054458977,0.00020455902,0.00055547914,0.00009483897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001316108,0.00027804205,0.0006797032,0.00020088533,0.00031723498,0.000043890162,0.00027438762,0.00033791224,0.0003336965],"category_scores_gemma":[0.00065346836,0.00019947668,0.00019019145,0.00027871018,0.00054731645,0.0000923758,0.00014375454,0.00051278435,0.000007740598],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012300974,0.0002445807,0.02584405,0.00003855157,0.00037200138,0.000004019304,0.00027402653,0.000012039701,0.17586389,0.00025552124,0.75339067,0.04357762],"study_design_scores_gemma":[0.0017884736,0.0014313632,0.01146044,0.00015211401,0.00029349455,0.00026676845,0.0007741733,0.00073280855,0.38370395,0.0034946625,0.5953315,0.00057024957],"about_ca_topic_score_codex":2.8757154e-7,"about_ca_topic_score_gemma":0.0000026266541,"teacher_disagreement_score":0.5750145,"about_ca_system_score_codex":0.000020580543,"about_ca_system_score_gemma":0.000059263413,"threshold_uncertainty_score":0.8134423},"labels":[],"label_agreement":null},{"id":"W4400830732","doi":"10.5639/gabij.2022.1103.018","title":"Key factors for successful uptake of biosimilars: Europe and the US","year":2022,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Key (lock); Business; Medicine; Computer science; Computer security; Internal medicine","score_opus":0.039403864860124246,"score_gpt":0.2793923534529661,"score_spread":0.23998848859284183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400830732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8418385,0.049835566,0.0057099923,0.09134991,0.004153075,0.0016764982,0.00311008,0.000061811406,0.0022645814],"genre_scores_gemma":[0.9160567,0.010920298,0.0054178494,0.066990666,0.00022016956,0.000065633074,0.00006456032,0.00007192002,0.00019218959],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99789464,0.00069277803,0.000603505,0.0003018051,0.00011433299,0.00039292005],"domain_scores_gemma":[0.99834365,0.0006946336,0.00046628152,0.00017281258,0.00025628906,0.00006636287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017193088,0.00026381738,0.000532087,0.00014945546,0.0011316324,0.00006317471,0.0003317276,0.00013612282,0.000307633],"category_scores_gemma":[0.00039268972,0.00015693739,0.00019866558,0.00034505027,0.000992359,0.000083072155,0.0003683352,0.00062053924,3.955348e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065930816,0.0011412746,0.042149536,0.00025183847,0.004598694,0.000064532775,0.008506111,0.00008030868,0.19572507,0.0057794377,0.70379794,0.03131216],"study_design_scores_gemma":[0.009301324,0.0023309921,0.023125974,0.00004682897,0.0007833984,0.0007511149,0.0049156477,0.00029217466,0.05592681,0.0051417723,0.896676,0.0007079309],"about_ca_topic_score_codex":8.2556465e-7,"about_ca_topic_score_gemma":0.0000031989628,"teacher_disagreement_score":0.19287807,"about_ca_system_score_codex":0.000025294343,"about_ca_system_score_gemma":0.000095588686,"threshold_uncertainty_score":0.8703716},"labels":[],"label_agreement":null},{"id":"W4401026458","doi":"10.5639/gabij.2023.1202.007","title":"Extrapolation requires reading between the lines","year":2023,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Connexins and lens biology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Extrapolation; Reading (process); Computer science; Mathematics; Statistics; Philosophy; Linguistics","score_opus":0.053973174812983755,"score_gpt":0.3021157404149194,"score_spread":0.24814256560193565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401026458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97421265,0.0014777265,0.0019498805,0.021055143,0.00039664216,0.000110070905,0.000056780336,0.000019381365,0.0007217015],"genre_scores_gemma":[0.9829309,0.0063326233,0.0003113719,0.008498975,0.0017586062,0.000005544502,0.0000887244,0.000016936703,0.000056298613],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99916583,0.00011528905,0.0002164095,0.00017972602,0.00009339533,0.00022936867],"domain_scores_gemma":[0.99952006,0.000053190834,0.00012994523,0.00012293283,0.00010570581,0.00006817538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052276393,0.00012208511,0.00011620922,0.000075464246,0.0003950257,0.00006564613,0.00013121024,0.00011827048,0.00001122247],"category_scores_gemma":[0.00012375285,0.000078535326,0.000068979534,0.00019258566,0.000124469,0.000006475948,0.00011074267,0.00015325232,0.0000034429306],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082158025,0.000022731341,0.099297345,0.000014470373,0.00029097943,0.000029585419,0.00053427886,0.000047567843,0.5122182,0.0000704082,0.3421789,0.045213357],"study_design_scores_gemma":[0.00085554825,0.00089600496,0.24845757,0.00004189047,0.00009504991,0.0002606816,0.001133175,0.00055114954,0.06578098,0.002689026,0.67870945,0.0005294607],"about_ca_topic_score_codex":2.4417642e-7,"about_ca_topic_score_gemma":0.0000049750156,"teacher_disagreement_score":0.4464372,"about_ca_system_score_codex":0.0000070752544,"about_ca_system_score_gemma":0.000044271015,"threshold_uncertainty_score":0.32025778},"labels":[],"label_agreement":null},{"id":"W4401026462","doi":"10.5639/gabij.2023.1202.008","title":"Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars","year":2023,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Perception; Medicine; Psychology; Internal medicine; Neuroscience","score_opus":0.039198613817649,"score_gpt":0.3057897446700765,"score_spread":0.2665911308524275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401026462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.735314,0.028239245,0.00068726356,0.21527527,0.0051931133,0.0010957288,0.0022523438,0.00036323132,0.011579789],"genre_scores_gemma":[0.89985746,0.031555135,0.003916426,0.06335044,0.00034092084,0.000026531428,0.00010851943,0.00007656997,0.0007679846],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.997969,0.00031506462,0.00042128522,0.00042622254,0.00009165423,0.0007767816],"domain_scores_gemma":[0.9990078,0.00017430981,0.00014047843,0.00018365674,0.00017995443,0.00031378574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078753,0.00032525006,0.00039411304,0.0005155073,0.0010890567,0.00018080072,0.00022810025,0.00041673574,0.0007247805],"category_scores_gemma":[0.00015744446,0.00025896935,0.00013064645,0.0005421172,0.00056247285,0.00017218453,0.00016733985,0.0006909252,0.000054901415],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006516959,0.00009612698,0.07973417,0.000057846002,0.00066032965,0.00023212048,0.0011407214,0.0000046867,0.077419996,0.00012180206,0.829183,0.011284076],"study_design_scores_gemma":[0.0024124146,0.0009734675,0.7326333,0.0002881951,0.0004280968,0.0035890853,0.003261081,0.00020976373,0.009667594,0.003764775,0.24133596,0.0014362793],"about_ca_topic_score_codex":0.00005402226,"about_ca_topic_score_gemma":0.0012766707,"teacher_disagreement_score":0.65289915,"about_ca_system_score_codex":0.00009937698,"about_ca_system_score_gemma":0.0002240171,"threshold_uncertainty_score":0.99998623},"labels":[],"label_agreement":null},{"id":"W4401034735","doi":"10.5639/gabij.2023.1201.006","title":"Non-medical switching of biologicals/biosimilars: Canada, Europe and the US – a webinar report","year":2023,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Business; Medicine; Internal medicine","score_opus":0.025111266278451654,"score_gpt":0.27459839568875927,"score_spread":0.24948712941030762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401034735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73611146,0.013843768,0.0018375843,0.24093637,0.0030371542,0.00065797917,0.00022660919,0.00008113575,0.0032679636],"genre_scores_gemma":[0.88148344,0.025827128,0.001265367,0.09079572,0.00034023784,0.000016767612,0.00003325153,0.000047125734,0.00019099457],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974793,0.00058937975,0.0008193578,0.0003753115,0.00021668256,0.00051993405],"domain_scores_gemma":[0.9981494,0.00070349127,0.00048623548,0.00022827547,0.00028318848,0.0001493866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031926972,0.00029093464,0.0006534833,0.00013644884,0.000553308,0.00005252012,0.00034549666,0.00034328067,0.00017288806],"category_scores_gemma":[0.0013878911,0.00015757966,0.00013088131,0.00060124614,0.0008632025,0.0000624979,0.00041042475,0.0008847802,0.000002878451],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007762004,0.00017572248,0.033673517,0.00009265411,0.00132589,0.0024188608,0.00052593526,0.000007289879,0.06569889,0.0003124132,0.8814104,0.013582204],"study_design_scores_gemma":[0.01181457,0.0016530233,0.20233801,0.00061459374,0.00081287866,0.018409973,0.002277947,0.00194031,0.04461482,0.0041451147,0.7097931,0.0015856969],"about_ca_topic_score_codex":0.00019958013,"about_ca_topic_score_gemma":0.0014890553,"teacher_disagreement_score":0.17161736,"about_ca_system_score_codex":0.000028582934,"about_ca_system_score_gemma":0.00050126563,"threshold_uncertainty_score":0.6425912},"labels":[],"label_agreement":null}]}